Correlation Between Ultragenyx and ProQR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Ultragenyx and ProQR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ultragenyx and ProQR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ultragenyx and ProQR Therapeutics BV, you can compare the effects of market volatilities on Ultragenyx and ProQR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ultragenyx with a short position of ProQR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ultragenyx and ProQR Therapeutics.

Diversification Opportunities for Ultragenyx and ProQR Therapeutics

0.71

Correlation Coefficient

Ultragenyx  ProQR Therapeutics

Poor diversification

The 3 months correlation between Ultragenyx and ProQR is 0.71. Overlapping area represents the amount of risk that can be diversified away by holding Ultragenyx and ProQR Therapeutics BV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ProQR Therapeutics and Ultragenyx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ultragenyx are associated (or correlated) with ProQR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ProQR Therapeutics has no effect on the direction of Ultragenyx i.e., Ultragenyx and ProQR Therapeutics go up and down completely randomly.

Pair Corralation between Ultragenyx and ProQR Therapeutics

Given the investment horizon of 90 days Ultragenyx is expected to generate 0.63 times more return on investment than ProQR Therapeutics. However, Ultragenyx is 1.58 times less risky than ProQR Therapeutics. It trades about -0.06 of its potential returns per unit of risk. ProQR Therapeutics BV is currently generating about -0.25 per unit of risk. If you would invest  4,227  in Ultragenyx on December 30, 2024 and sell it today you would lose (445.00) from holding Ultragenyx or give up 10.53% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Ultragenyx  vs.  ProQR Therapeutics BV

Ultragenyx

Risk-Adjusted Performance

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

ProQR Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days ProQR Therapeutics BV has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Ultragenyx and ProQR Therapeutics

The main advantage of trading using opposite Ultragenyx and ProQR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ultragenyx position performs unexpectedly, ProQR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will offset losses from the drop in ProQR Therapeutics' long position.

The idea behind Ultragenyx and ProQR Therapeutics BV pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.